Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma Meeting Abstract
| Authors: | Batlevi, C. L.; Park, S. I.; Nastoupil, L.; Phillips, T.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Pagel, J. M.; Leonard, J. P.; Yang, J.; O'Connor, H.; Hamlett, A.; Adib, D.; Morschhauser, F. |
| Abstract Title: | Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413900205 |
| DOI: | 10.1182/blood-2021-148199 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2207 -- Hybrid meeting, also took place online -- Source: Wos |
